First Capital Advisors Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

First Capital Advisors Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-400	Closed	-$1K	–	783
2018 Q1	$1K	Buy	+400	New	+$36.5K	﹤0.01%	845

Other funds holding XBI

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

First Capital Advisors Group's XBI Position: Q4 2018 in Review

First Capital Advisors Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2018, closing a stake of 2,763 shares — an estimated $265K sold.

First Capital Advisors Group first reported a position in XBI in Q4 2016 and held it in 8 quarters. The position peaked at $741K in Q1 2017. 427 funds tracked by Wall St. Rank hold XBI as of Q4 2018.

First Capital Advisors Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2018 after selling out during the quarter.
First Capital Advisors Group sold 2,763 State Street SPDR S&P Biotech ETF shares in Q4 2018, an estimated $265K.
First Capital Advisors Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and held it in 8 quarters.
First Capital Advisors Group's State Street SPDR S&P Biotech ETF position peaked at $741K in Q1 2017.
427 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2018.

Based on First Capital Advisors Group's 13F filing for Q4 2018, filed 7 Feb 2019.